Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513563 · ClinicalTrials.gov registry record · Phase 2
AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT02513563 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 42 participants.
The verdict
NCT02513563, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG AZD1775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02513563
The ClinicalTrials.gov registry entry for NCT02513563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02513563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02513563 about?
NCT02513563 is a clinical study titled "AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer". The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.
What is the current status of trial NCT02513563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2015-10-13. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT02513563?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), AZD1775 (DRUG).
Who is sponsoring clinical trial NCT02513563?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.